Antiviral compounds
US-9428469-B2 · Aug 30, 2016 · US
US9693997B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9693997-B2 |
| Application number | US-201414768915-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 3, 2014 |
| Priority date | Mar 6, 2013 |
| Publication date | Jul 4, 2017 |
| Grant date | Jul 4, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
Opening claim text (preview).
The invention claimed is: 1. A compound of formula I: wherein: A is phenyl, naphthyl, or bicyclic unsaturated or partially saturated heteroaryl, substituted with one or more A; each A is independently lower alkyl, halo, lower alkoxy, S(═O) 2 (CH 2 ) m A″, C(═O)NHA″, NHC(O)A″, —O(CH 2 ) m A″, (CHA 1 ) m NHS(═O) 2 A 1 ; or S(═O) 2 NHA″; each A″ is independently, heterocycloalkyl or heteroaryl, optionally substituted with one or more A′″; each A′″ is independently hydroxy, lower alkyl, oxo, C(═O)OA 1 , halo loweralkyl, each A 1 is independently H, lower alkyl, halo loweralkyl, amino, lower alkoxy, each m is independently 0, 1, 2, or 3; R 1 is H, halo, lower alkyl, halo loweralkyl, SF 5 , and R 2 is H, halo, lower alkyl, halo loweralkyl, or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , wherein A is phenyl. 3. The compound of claim 2 , wherein R 1 is halo loweralkyl. 4. The compound of claim 3 , wherein R 2 is halo. 5. The compound of claim 2 , wherein R 1 is halo. 6. The compound of claim 5 , wherein R 2 is halo. 7. The compound of claim 1 , wherein A′ is S(═O) 2 (CH 2 ) m A″ or (CH 2 ) m S(═O) 2 A″. 8. The compound of claim 1 , wherein A′ is lower alkyl, halo, or lower alkoxy. 9. The compound of claim 1 , wherein A′ is C(═O)NHA″ or NHC(═O)A″. 10. The compound of claim 1 , wherein A′ is (CHA 1 ) m NHS(═O) 2 A 1 or S(═O) 2 NHA″. 11. The compound of claim 1 , wherein A′ is O(CH 2 ) m A″. 12. A compound selected from the group consisting of: 4-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonyl]-piperidine-1-carboxylic acid tert-butyl ester; 3-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonylmethyl]-piperidine-1-carboxylic acid tert-butyl ester; (S)-1-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluormethyl-biphenyl-4-sulfonyl]-pyrrolidine-2-carboxylic acid tert-butyl ester; N 3 -{6-Chloro-2-trifluoromethyl-4′-[1-(3,3,3-trifluoro-propyl)-piperidine-4-sulfonyl]-biphenyl-4-yl}-1H-[1,2,4]triazole-3,5-diamine; N 3 -{6-Chloro-4′-[1-(3,3-dimethyl-butyl)-piperidine-4-sulfonyl]-2-trifluoromethyl-biphenyl-4-yl}-H-[1,2,4]triazole-3,5-diamine; 3-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonyl]-piperidine-1-carboxylic acid tert-butyl ester; 4-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonylmethyl]-piperidine-1-carboxylic acid tert-butyl ester; 4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-biphenyl-4-carboxylic acid tert-butylamide; Pentanoic acid [4′-(5-amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-biphenyl-4-yl]-amide; N 3 -[4-(2-tert-Butyl-1,1-dioxo-2,3-dihydro-1H-1λ 6 -benzo[d]isothiazol-6-yl)-3-chloro-5-trifluoromethyl-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -{6-Chloro-2-trifluoromethyl-4′-[1-(3,3,3-trifluoro-propyl)-piperidine-3-sulfonyl]-biphenyl-4-yl}-1H-[1,2,4]triazole-3,5-diamine; N-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-biphenyl-4-ylmethyl]-methanesulfonamide; N—{(S)-1-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-yl]-ethyl}-methanesulfonamide; N 3 -(2,6-Dichloro-4′-methanesulfonyl-3′-trifluoromethyl-biphenyl-4-yl)-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3,5-Dichloro-4-(1-methanesulfonyl-1H-indol-4-yl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; 4-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonyl]-piperazine-1-carboxylic acid tert-butyl ester; N 3 -{6-Chloro-4′-[1-(3,3-dimethyl-butyl)-piperidine-3-sulfonyl]-2-trifluoromethyl-biphenyl-4-yl}-1H-[1,2,4]triazole-3,5-diamine; 4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-4-methyl-6′-trifluoromethyl-biphenyl-3-sulfonic acid tert-butylamide; N 3 -[2-Chloro-4′-methoxy-3′-(propane-2-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[2-Chloro-4′-(piperidine-4-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; 4-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-3-yloxy]-piperidine-1-carboxylic acid tert-butyl ester; N 3 -[2-Chloro-4′-(4-methyl-piperazine-1-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[2-Chloro-6-fluoro-4′-(propane-2-sulfonyl)-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N—{(R)-1-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-yl]-ethyl}-methanesulfonamide; N 3 -[2-Chloro-4′-(piperidin-3-ylmethanesulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; 4-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-biphenyl-4-yloxy]-butyronitrile; 4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonic acid ((S)-1-pyrolidin-2-ylmethyl)-amide; N-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-2-fluoro-biphenyl-4-yl]-methanesulfonamide; N 3 -[2-Chloro-4′-(piperidine-3-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -(2-Chloro-6-fluoro-4′-methanesulfonyl-biphenyl-4-yl)-1H-[1,2,4]triazole-3,5-diamine; N 3 -(2,6-Dichloro-4′-methanesufonylmethyl-biphenyl-4-yl)-1H-[1,2,4]triazole-3,5-diamine; N 3 -[4′-(Azetidin-3-ylmethoxy)-2,6-dichloro-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[2-Chloro-4′-(piperazine-1-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; 4′(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-fluoro-biphenyl-4-sulfonic acid dimethylamide; N 3 -[2-Chloro-4′-((S)-1-pyrrolidin-2-ylmethanesulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[2-Chloro-4′-(morpholine-4-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[4′-(Azetidin-3-ylmethoxy)-2-chloro-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N-{2-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-yl]-ethyl}-methanesulfonamide; 5-((3aR,6S,6aS)-2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoic acid [4′-(5-amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-biphenyl-4-yl]-amide; N 3 -[2-Chloro-4′-(piperidin-4-ylmethanesulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[2-Chloro-3′-(piperidin-4-yloxy)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3,5-Dichloro-4-(1-methanesulfonyl-1H-indol-5-yl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; 1-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-biphenyl-4-yl]-pyrrolidin-2-one; N 3 -[3-Chloro-4-(4-methanesulfonyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-5-trifluoromethyl-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[2-Chloro-4′-(1,1-dioxo-1λ 6 -thiomorpholine-4-sulfonyl)-6-trifluoromethyl-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; N-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′,6′-dichloro-3-fluoro-biphenyl-4-yl]-methanesulfonamide; 6-[4-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2-chloro-6-trifluoromethyl-phenyl]-4H-benzo[1,4]oxazin-3-one; N 3 -(2,6-Dichloro-biphenyl-4-yl)-1H-[1,2,4]triazole-3,5-diamine; N 3 -[4′-(4-Amino-butoxy)-2,6-dichloro-biphenyl-4-yl]-1H-[1,2,4]triazole-3,5-diamine; compound with trifluoro-acetic acid; N 3 -(4′-Amino-2,6-dichloro-biphenyl-4-yl)-1H-[1,2,4]triazole-3,5-diamine; (S)-1-[4′-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2′-chloro-6′-trifluoromethyl-biphenyl-4-sulfonyl]-pyrrolidine-2-carboxylic acid; N 3 -[3,5-Dichloro-4-(2,2-dimethyl-4,4-dioxo-3,4-dihydro-2H-4λ 6 -benzo[1,4]oxathiin-6-yl
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
for RNA viruses · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.